Abbvie Inc (ABBV) is overvalued and Astrazeneca plc (AZN) is slightly undervalued.
Against our estimates of intrinsic value, AZN trades at the wider discount: a margin of safety of +7%, against -148% for ABBV.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $106.86; the price of $265.21 is 148% above that value, and 83% of that value comes from beyond year five.
Leak Score 57/100 on 8 of 12 signals
Discounting its cash flows at 7.4% (average of 3 methods) values the shares at $180.20; the price of $168.37 is 7% below that value, and 82% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
| Metric | ABBV | AZN |
|---|---|---|
| Verdict | Overvalued | Slightly undervalued |
| Price | $265.21 | $168.37 |
| Intrinsic value | $106.86 | $180.20 |
| Margin of safety | -148% | +7% |
| Leak Score | 57/100 (8/12) | 59/100 (3/12) |
| Market cap | $468.7B | $261.1B |
| Revenue growth, 5 years | 6.0% | 16.3% |
| Operating margin | 34.2% | 22.4% |
| Net margin | 9.7% | 17.0% |
| Return on equity | 15221.8% | 22.0% |
| Debt to equity | — | 0.64 |
| P/E | 75.0x | 25.2x |
| Forward P/E | 16.2x | 14.6x |
| P/B | — | 5.2x |
| Dividend yield | 2.6% | 2.0% |